- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05730517
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters (TO-COSKIN-2)
December 8, 2023 updated by: VIST - Faculty of Applied Sciences
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters: Double Blind, Placebo-controlled, Randomised Three-way Study Comparing the Efficacy of Two Test Products
The aim of the randomized, double-blind, placebo-controlled, one-period effectiveness study is to compare the effects of multiple-dose 16 weeks daily dietary supplementation with 5 g collagen alone or 5 g of collagen in combination with hyaluronic acid on skin in healthy human subjects in comparison to placebo product.
The main objective is to show that test products have beneficial effects on dermis density, and also on other skin parameters and to investigate differences in the effects among test products.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Single centre, randomized, double-blind, placebo-controlled, one-period effectiveness study will include 84 subjects.
Subjects will be divided in three groups, 28 in each.
Test group 1 (TG1) will receive investigational product 1 (CP5HA, daily dose 15 mL: collagen 5 g, hyaluronic acid (HA): 30 mg, vitamin C: 80 mg), test group 2 (TG2) will receive investigational product 2 (CP5, daily dose 15 mL: collagen 5 g, vitamin C: 80 mg) and the placebo group (PG) will receive placebo product without those active ingredients (15 mL: 0 g collagen, 0 g HA, 0 g vitamin C).
Participants will test continuous administration of placebo or investigational products for 16 weeks in order to demonstrate and assess multiple-dose effects.
Study Type
Interventional
Enrollment (Actual)
87
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- VIST - Faculty of Applied Sciences, Institute of Cosmetics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria:
- Caucasian female volunteers aged between 40 and 65 years at the time of the signature of Informed consent form (ICF),
- Signed Informed consent form (ICF),
- Fitzpatrick skin phototypes I-IV,
- Signs of skin aging,
- In good general health condition,
- Body mass index (BMI) < 35
- Willingness to avoid a consumption of any food supplements containing hyaluronic acid, methylsulfonylmethane (MSM), antioxidants, collagen and other protein-based food supplements during the study,
- Willingness to follow all study procedures and keeping a diary during the study (to follow their compliance and palatability).
- Willingness to maintain their living habits and to not begin or change any estrogen or progesterone therapies,
- Willingness to avoid shaving/depilation of their arms during the study,
- Willingness not to change cosmetic treatment routine during the study,
- Willingness to avoid rejuvenation treatments during the study.
Exclusion criteria:
- Pregnancy or breastfeeding,
- Known or suspected allergy to any ingredient of the tested products,
- Changes in dietary habits and dietary supplementation in the last three months prior to inclusion,
- Regular use of food supplements containing MSM, antioxidants, collagen or other protein-based food supplements in the last three months prior to inclusion,
- Veganism,
- Changes in cosmetic facial and body care routine in the last month prior to inclusion,
- Diagnosed and uncontrolled/unregulated disease,
- Any clinically significant history of serious metabolic disease, digestive tract disease, liver disease, kidney disease, hematological disease,
- Intake of drugs with any impact on skin reactions (e.g., glucocorticoids, antihistamines, and immunomodulators),
- Any clinically significant acute or chronic skin diseases,
- Skin pigmentation disorders on measuring sites,
- Anticipated sunbathing or solarium visits before or during the study,
- Invasive rejuvenation treatments (e.g. needle rollers, needle mesotherapy, deep/medium-deep chemical peels, abrasive laser treatments etc.) in the last 4 months prior to study entry,
- Non-invasive rejuvenation treatments (e.g. radiofrequency, electrotherapy, ultrasound, intense pulsed light therapy (IPL), non-abrasive laser treatments) in the last month prior to study entry,
- Shaving/depilation of the arms in the last 14 days before inclusion,
- Mental incapacity that precludes adequate understanding or cooperation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Test group 1 (CP5HA Group)
Participants will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL).
|
Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
|
|
Placebo Comparator: Placebo group
Placebo group participants will receive placebo syrup without active ingredients.
(daily dose 15 mL: collagen: 0 mg, HA: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
|
Placebo group will receive placebo syrup without active ingredients.
(daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
|
|
Active Comparator: Test group 2 (CP5 Group)
Participants will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 15 mL).
|
Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of dermis density from baseline in all test groups in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
Significant change of dermis density from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation with study product is expected.
Dermis density will be assessed through ultrasonographic dermis intensity measurement.
Differences in change of dermis density between test groups under primary objective conditions will also be evaluated.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of wrinkle volume from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
Assessment of the effects of investigational product on periorbital wrinkles after 16 weeks of dietary supplementation will be done using topography measurements.
Differences between test groups will also be evaluated.
|
16 weeks
|
|
Change of skin texture from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
For assessments of skin texture topography roughness measurements (Ra, Rq) will be performed.
Significant changes from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation is expected.
Differences between test groups will also be evaluated.
|
16 weeks
|
|
Change of skin hydration from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
Assessment of the effects of the investigational product on skin hydration after 16 weeks of dietary supplementation.
Skin hydration measurements will be performed using conductance principle.
Differences between test groups will also be evaluated.
|
16 weeks
|
|
Change of dermis thickness from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
Significant change of dermis thickness from baseline in test group, in comparison to placebo group after 16 weeks of dietary supplementation with study product is expected.
Dermis density will be assessed using ultrasonography.
Differences between test groups will also be evaluated.
|
16 weeks
|
|
Change of skin elasticity from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation
Time Frame: 16 weeks
|
Significant change of skin elasticity from baseline in test groups, in comparison to placebo group after 16 weeks of dietary supplementation with study products is expected.
Skin elasticity will be assessed using viscoleasticity measurement (Units of Measure: MPa).
Differences between test groups will also be evaluated.
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Katja Žmitek, PhD, Head of Reasearch Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2023
Primary Completion (Actual)
July 30, 2023
Study Completion (Actual)
October 10, 2023
Study Registration Dates
First Submitted
January 31, 2023
First Submitted That Met QC Criteria
February 13, 2023
First Posted (Actual)
February 16, 2023
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- VIST TO-COSKIN-2 01-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wrinkles
-
Ulthera, IncTerminatedPeri-oral Wrinkles | Peri-orbital WrinklesUnited States
-
CLASSYS Inc.CompletedWrinkles | Facial Wrinkles | Wrinkles Such as Nasolabial Folds | Anti-Aging | Wrinkles and RhytidesChina
-
Cynosure, Inc.CompletedPeri-oral Wrinkles | Peri-orbital WrinklesUnited States
-
Anika Therapeutics, Inc.Completed
-
Ivo Pitanguy InstituteAllerganCompleted
-
Skincare Physicians of Chestnut HillGalderma R&DRecruitingPerioral WrinklesUnited States
-
Merz North America, Inc.Active, not recruitingDécolleté WrinklesUnited States
-
Galderma R&DCompletedCheek WrinklesUnited States
-
Ulthera, IncCompleted
-
Deka Medical, Inc.CompletedWrinkles | RhytidesUnited States